Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H+ ,K+ )-ATPase in the gastric parietal cell. By acting specifically on the proton pump, dexlansoprazole blocks the final step of acid production.

DEXILANT is a proton pump inhibitor (PPI) indicated for: • Healing of all grades of erosive esophagitis (EE). • Maintaining healing of EE and relief of heartburn. • Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).

• Healing of EE: 60 mg once daily for up to 8 weeks. • Maintenance of healed EE: 30 mg once daily for up to 6 months. • Symptomatic non-erosive GERD: 30 mg once daily for 4 weeks. • Hepatic impairment: Consider 30 mg maximum daily dose for patients with moderate hepatic impairment (Child-Pugh Class B). No studies were conducted in patients with severe hepatic impairment (Child-Pugh Class C). • DEXILANT can be taken without regard to food. • DEXILANT should be swallowed whole. Alternatively, capsules can be opened, sprinkled on one tablespoon of applesauce, and swallowed immediately.

Most commonly reported adverse reactions (≥2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Patients with known hypersensitivity to any component of the formulation.

• Gastric Malignancy: Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. • Clostridium difficile associated diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea. • Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. • Hypomagnesemia: Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.